
NanoViricides NNVC
$ 1.46
0.0%
Quarterly report 2025-Q4
added 02-17-2026
NanoViricides Long Term Debt Current 2011-2026 | NNVC
Annual Long Term Debt Current NanoViricides
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | - | - | - | - | - | - | 5.47 M | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 5.47 M | 5.47 M | 5.47 M |
Long Term Debt Current of other stocks in the Biotechnology industry
| Issuer | Long Term Debt Current | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
FSD Pharma
HUGE
|
103 K | - | 5743.5 % | $ 69.7 M | ||
|
MorphoSys AG
MOR
|
3.63 M | - | 2.43 % | $ 254 M | ||
|
MannKind Corporation
MNKD
|
2.11 M | $ 3.56 | 24.48 % | $ 1.09 B | ||
|
AgeX Therapeutics
AGE
|
181 K | - | -10.17 % | $ 12.2 K | ||
|
I-Mab
IMAB
|
8.06 M | - | - | $ 866 M | ||
|
Bio-Techne Corporation
TECH
|
14.1 M | $ 47.41 | -16.36 % | $ 7.47 B | ||
|
Athira Pharma
ATHA
|
465 K | - | - | $ 269 M | ||
|
BioNTech SE
BNTX
|
45 M | - | - | $ 27.2 B | ||
|
INmune Bio
INMB
|
623 K | $ 1.52 | -1.3 % | $ 37.6 M | ||
|
Exelixis
EXEL
|
27.9 M | $ 48.7 | 9.64 % | $ 13.2 B | ||
|
ACADIA Pharmaceuticals
ACAD
|
9.96 M | $ 21.48 | -3.89 % | $ 3.56 B | ||
|
Fortress Biotech
FBIO
|
2.13 M | - | - | $ 71.1 M | ||
|
Advaxis
ADXS
|
166 K | - | -9.65 % | $ 45.9 M | ||
|
Esperion Therapeutics
ESPR
|
2.1 M | $ 3.15 | 1.19 % | $ 655 M | ||
|
Can-Fite BioPharma Ltd.
CANF
|
43 K | - | - | $ 5.51 M | ||
|
Aeterna Zentaris
AEZS
|
215 K | - | 5.93 % | $ 314 M | ||
|
Aeglea BioTherapeutics
AGLE
|
625 K | - | - | $ 1.01 B | ||
|
CureVac N.V.
CVAC
|
3.47 M | - | - | $ 867 M | ||
|
Applied Genetic Technologies Corporation
AGTC
|
1.27 M | - | - | $ 26.5 M | ||
|
AIkido Pharma
AIKI
|
554 K | - | 1.93 % | $ 17.4 M | ||
|
Aptose Biosciences
APTO
|
193 K | - | -45.71 % | $ 1.2 M | ||
|
Aptinyx
APTX
|
337 K | - | -39.0 % | $ 4.57 M | ||
|
Akouos
AKUS
|
671 K | - | 0.23 % | $ 488 M | ||
|
Albireo Pharma
ALBO
|
3.08 M | - | -0.23 % | $ 916 M | ||
|
Allakos
ALLK
|
3.25 M | - | - | $ 28.6 M | ||
|
AlloVir
ALVR
|
316 K | - | 4.14 % | $ 49.1 M | ||
|
Arcutis Biotherapeutics
ARQT
|
294 K | $ 24.17 | 3.2 % | $ 3.08 B | ||
|
Allena Pharmaceuticals
ALNA
|
317 K | - | 3.16 % | $ 1.9 M | ||
|
Ampio Pharmaceuticals
AMPE
|
274 K | - | -11.43 % | $ 502 K | ||
|
Applied Molecular Transport
AMTI
|
4.64 M | - | - | $ 10.1 M | ||
|
Alpine Immune Sciences
ALPN
|
756 K | - | - | $ 2.17 B | ||
|
Aileron Therapeutics
ALRN
|
48 K | - | 10.36 % | $ 9.8 M | ||
|
Applied Therapeutics
APLT
|
429 K | - | - | $ 8.42 M | ||
|
Aravive
ARAV
|
2.2 M | - | -13.39 % | $ 1.45 M | ||
|
Aridis Pharmaceuticals
ARDS
|
538 K | - | 17.91 % | $ 11.1 M | ||
|
CRISPR Therapeutics AG
CRSP
|
18.6 M | $ 55.08 | 5.15 % | $ 4.95 B | ||
|
Autolus Therapeutics plc
AUTL
|
4.56 M | $ 1.7 | 3.66 % | $ 452 M | ||
|
AVROBIO
AVRO
|
878 K | - | 1083.1 % | $ 745 M | ||
|
Ayala Pharmaceuticals
AYLA
|
419 K | - | - | $ 7.46 M |